US Bankruptcy Chapter 11 Insolvency SEC Filings — March 27, 2026

Filed Irish High Court winding-up petition March 27, 2026, due to limited cash resources and high operating costs outstripping modest ORLYNVAH sales

Nasdaq listing non-compliance persisting, increasing delisting risk and share illiquidity

Failed acquisition talks for sulopenem asset, eliminating potential value-extracting M&A pathway

Provisional liquidators appointed (Damien Murran, Jennifer McMahon), signaling control shift from management and likely asset liquidation

ORLYNVAH faces potential U.S. market withdrawal by liquidators, halting revenue stream with no YoY growth visibility

No capital allocation activity (dividends, buybacks) amid cash constraints, prioritizing survival over shareholder returns

Irish subsidiary also under provisional liquidation, amplifying operational wind-down across entities

Negative sentiment across all metrics with no forward-looking guidance for recovery, contrasting typical biotech turnaround narratives

High materiality (10/10) event erodes enterprise value, with no insider buying to signal conviction

No period-over-period improvements in cash position or sales volumes, underscoring terminal decline

Winding-up petition filed March 27, 2026, with hearing April 13, 2026, potentially leading to full dissolution

Limited cash resources cited as primary trigger, with high operating costs vs. modest ORLYNVAH sales indicating unsustainable runway

Ongoing Nasdaq issues heighten delisting probability, impairing liquidity and access

Collapsed sulopenem acquisition talks remove last viable strategic lifeline

Provisional liquidators may pull ORLYNVAH from U.S. market, zeroing near-term revenue

Irish subsidiary liquidation appointment compounds parent-level distress

Absence of insider purchases amid crisis signals zero management conviction

Stakeholder inquiries directed to Iterum.Liquidation@teneo.com, subordinating equity holders

Imminent April 13 hearing likely accelerates share price collapse from liquidation fears, ideal for put options or shorts

Trade gap-down on petition news, with no recovery catalysts post-filing

Monitor liquidators for sulopenem or ORLYNVAH fire-sale bids, potential for vulture investors

Short Iterum vs. long stable biotech peers, capitalizing on sector decile underperformance

Equity wipeout favors early creditor claims via teneo.com inquiries ahead of hearing

Position for Nasdaq delisting discount, with OTC trading premium erosion

Elevated implied volatility on puts post-petition, attractive for short premium decay if delayed

Use as biotech insolvency proxy to hedge small-cap pharma exposure

Single filing exemplifies small-cap biotech vulnerability, with cash resources depleted vs. high costs and no YoY sales acceleration

Modest ORLYNVAH sales highlight post-approval revenue shortfalls in niche antimicrobials, pressuring similar late-stage assets

Failed M&A for key assets like sulopenem underscores acquisition drought in distressed biotech

Provisional liquidators' product withdrawal powers signal rapid U.S. market exits, disrupting supply chains

Non-compliance as insolvency precursor, amplifying delisting risks for cash-strapped listings

Monitor outcome of winding-up petition hearing for confirmation of full liquidation [April 13, 2026]

Track decisions on ORLYNVAH U.S. withdrawal and sulopenem disposition by Damien Murran/Jennifer McMahon [Ongoing]

Watch for creditor communications via Iterum.Liquidation@teneo.com for claim priorities [Immediate]

Any delisting notices or compliance extensions amid liquidation proceedings [Next 30 days]

Developments in Irish subsidiary liquidation impacting parent assets [Post-April 13]

Scan for any 4/13G activity signaling pledges or sales during distress [Ongoing]

Potential fire-sales of IP or inventory by liquidators creating bid opportunities [Q2 2026]